Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney drug tested in diabetic vs non-diabetic patients – results may guide future care

NCT ID NCT07302464

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a class of diabetes drugs called SGLT2 inhibitors changes kidney function in people with chronic kidney disease (CKD). Researchers compared 60 patients with and without diabetes to see if the drug affects their estimated glomerular filtration rate (eGFR) differently. The goal was to understand whether these drugs benefit both groups, not just those with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Oct 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This case-control study was done on 60 adult chronic kidney disease (CKD) individuals with stage 3 and 4 (eGFR\>\_20ml/min/1.73 m2) according to KIDGO classification at Ain Shams University Hospitals, Cairo, Egypt.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * Chronic kidney disease (CKD) participants with stages 3 and 4. Exclusion Criteria: * Patients with type 1 diabetes mellitus (DM). * Patients with decompensated Chronic liver disease. * Patients with uncontrolled hypertension. * Patients with blood pressure (BP) \> 110/70. * Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors). * Patients with a history of recurrent or recent urinary tract infection (UTI). * Patients with glycated hemoglobin (HbA1c) ≤10. * Adult polycystic kidney disease. * All patients on immunosuppressive medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ain Shams University

    Cairo, 11591, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.